OUR PIPELINE
We aspire to operate one of the most productive R&D engines in the biopharma industry.
Our broad, diverse pipeline of novel, first-in-class medicines spans multiple therapeutic areas and diseases. Every program focuses on a large market indication with high unmet needs and a common goal: delivering outsized impact for patients.
We have built our company around core scientific values that frame our approach to drug discovery and development.
Our Core ValuesLatest News
NGM621 for Geographic Atrophy (GA)
NGM621, our anti-complement C3 antibody, is currently in Phase 2 study (CATALINA) as a treatment to potentially reduce disease progression in patients with GA and with the potential for every eight week dosing.
Learn MoreWorking Here
Our People Are Our Platform.
What makes NGM tick? Really smart team members who love working together to pursue great science and share a common drive to deliver a huge impact for patients. We have no hierarchies. We collaborate intensively, embrace risk freely and always swing for the fence.
Join Us